Galvus

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 2005531
                    [Title] => First data verify value of early combination therapy in T2D
                    [Summary] => Upfront use of a dual combination of vildagliptin (Galvus) and metformin was associated with better and more durable glycemic control than metformin alone in patients with newly diagnosed type 2 diabetes, according to findings reported at the annual meeting of the European Association for the Study of Diabetes.
                    [DatePublished] => 2020-04-05 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

First data verify value of early combination therapy in T2D

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | April 5, 2020 - 12:00am

Upfront use of a dual combination of vildagliptin (Galvus) and metformin was associated with better and more durable glycemic control than metformin alone in patients with newly diagnosed type 2 diabetes, according...

Opinion